Puma Biotechnology Sets New 12-Month High at $243.31 (PBYI)
Puma Biotechnology (NASDAQ:PBYI)’s share price reached a new 52-week high during mid-day trading on Friday , ARN reports. The company traded as high as $243.31 and last traded at $240.88, with a volume of 227,136 shares traded. The stock had previously closed at $235.01.
Several analysts have recently commented on the stock. Analysts at Citigroup Inc. raised their price target on shares of Puma Biotechnology from $99.00 to $292.00 in a research note on Wednesday, July 23rd. They now have a “buy” rating on the stock. Separately, analysts at Leerink Swann raised their price target on shares of Puma Biotechnology from $144.00 to $300.00 in a research note on Wednesday, July 23rd. They now have an “outperform” rating on the stock.
The stock has a 50-day moving average of $118.0 and a 200-day moving average of $100.3. The company’s market cap is $7.302 billion.
Puma Biotechnology (NASDAQ:PBYI) last released its earnings data on Monday, May 12th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by $0.19. Analysts expect that Puma Biotechnology will post $-3.51 EPS for the current fiscal year.
Puma Biotechnology, Inc is a development-stage biopharmaceutical company that acquires and develops products for the treatment of various forms of cancer.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.